A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.
Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.
Genetically modifying immune cells might effectively treat multiple myeloma, according to a new study.
Blacks may be twice as likely as whites to develop multiple myeloma because they are more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance.
The most comprehensive genetic study to date of the blood cancer multiple myeloma has revealed that the genetic landscape of the disease may be more complicated than previously thought.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|